Please assess the completion status of the following clinical trial:

Trial Title: A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Macular edema associated with diabetic retinopathy~* Decreased visual acuity attributable primarily to DME~* Diagnosis of diabetes mellitus~Exclusion Criteria:~* High risk proliferative diabetic retinopathy~* Cataract surgery within 3 months of Baseline, or any other previous intraocular surgery~* Uncontrolled glaucoma~* Current or history of ocular disease in the study eye other than DME~* Major illness or major surgical procedure within 1 month prior to Day 1~* Uncontrolled blood pressure~* Glycosylated hemoglobin (HbA1c) greater than (\>) 12 percent (%) at screening~* Untreated diabetes mellitus or initiation of oral anti-diabetic medication or insulin within 4 months prior to Day 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: 0.3 mg Ranibizumab (Type: ACTIVE_COMPARATOR): Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
- Arm B: 1.5 mg Faricimab (Type: EXPERIMENTAL): Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
- Arm C: 6 mg Faricimab (Type: EXPERIMENTAL): Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).